δ-opioid receptor

δ-opioid receptor
Name	δ-opioid receptor
HGNCid	8155
EntrezGene	4985
OMIM	165195
RefSeq	NM_000911
UniProt	P41143
Band	34.3

δ-opioid receptor. The δ-opioid receptor, encoded by the OPRD1 gene, is a class A G protein-coupled receptor that is one of the four major opioid receptor types in the mammalian nervous system. It is primarily activated by endogenous enkephalin peptides and mediates a range of neuromodulatory effects, including analgesia, mood regulation, and reward processing. While its discovery followed that of the μ-opioid receptor, it has become a distinct target for developing novel therapeutics with potentially fewer side effects than traditional opioid drugs.

Structure and function

The δ-opioid receptor is a member of the rhodopsin-like family of G protein-coupled receptors, characterized by seven transmembrane domains. Its activation primarily couples to inhibitory Gαi/o protein subunits, leading to the inhibition of adenylyl cyclase activity and a reduction in intracellular cyclic AMP levels. This signaling cascade results in the modulation of various ion channels, including the opening of potassium channels and the closing of voltage-gated calcium channels, which hyperpolarizes neurons and reduces neurotransmitter release. The receptor's intracellular loops and C-terminus contain sites for phosphorylation by G protein-coupled receptor kinases and interaction with β-arrestin, which are critical for its desensitization and internalization.

Gene and expression

The gene encoding the δ-opioid receptor, OPRD1, is located on chromosome 1 in humans, at position 1p34.3. The gene's expression is regulated by various transcription factors and epigenetic mechanisms, leading to a distinct distribution pattern within the central nervous system and peripheral nervous system. High levels of receptor expression are found in regions such as the olfactory bulb, neocortex, basal ganglia, and limbic system structures like the hippocampus and amygdala. This distribution correlates with its involvement in olfaction, cognition, motor control, and emotional processing. Expression is also detected in peripheral tissues, including the gastrointestinal tract and immune cells.

Ligands and pharmacology

The primary endogenous agonists for the δ-opioid receptor are the enkephalin peptides, Met-enkephalin and Leu-enkephalin. Selective synthetic agonists include SNC80 and DPDPE, while naltrindole is a prototypical selective antagonist. These ligands have been instrumental in delineating the receptor's functions in preclinical studies. The receptor exhibits a complex pharmacology, with ligands often demonstrating functional selectivity or biased agonism, preferentially activating either G protein or β-arrestin signaling pathways. This property is a major focus for drug development, aiming to harness therapeutic effects like analgesia while minimizing adverse effects such as convulsions historically associated with early δ-agonists.

Physiological roles

Activation of δ-opioid receptors modulates a wide array of physiological processes. In the context of nociception, it produces analgesia, particularly for chronic inflammatory and neuropathic pain states, often exhibiting synergistic effects with μ-opioid receptor activation. Within the mesolimbic pathway, it influences dopamine release and is implicated in the rewarding properties of drugs and natural behaviors. The receptor also plays a role in regulating mood and affective states, with evidence pointing to antidepressant and anxiolytic-like effects in animal models. Additional roles include the modulation of gastrointestinal motility, neuroprotection, and the regulation of immune response.

Clinical significance

The δ-opioid receptor is a promising target for novel therapeutic agents. Its engagement is being explored for the treatment of chronic pain conditions, with the goal of achieving analgesia without the respiratory depression, constipation, and high addiction liability associated with μ-opioid receptor drugs like morphine. Furthermore, its role in emotional regulation has spurred research into δ-agonists as potential antidepressants and anxiolytics, as evidenced by clinical trials with compounds like AZD2327. Antagonists targeting this receptor are also investigated for treating cocaine addiction and alcohol use disorder, given its involvement in reward pathways.

Research history

The δ-opioid receptor was first proposed as a distinct entity based on pharmacological studies in the 1970s, following the characterization of the μ-opioid receptor and κ-opioid receptor. Its existence was confirmed in 1992 with the successful cloning of the receptor cDNA from a NG108-15 neuroblastoma-glioma hybrid cell line by teams led by Brigitte Kieffer and others. This cloning, achieved concurrently by researchers including Christopher Evans, opened the door for molecular characterization and the development of genetically modified mouse models. Landmark studies using knockout mice from the laboratories of John Pintar and Brigitte Kieffer in the 1990s were crucial for defining its in vivo functions in pain, emotion, and reward.

Category:G protein-coupled receptors Category:Opioid receptors Category:Neurology Category:Neuropharmacology